Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen

被引：0
|
作者：
Shinmi, Daisuke [1 ]
Masuda, Kazuhiro [2 ]
机构：
[1] Kyowa Hakko Kirin Co Ltd, Antibody & Biol Res Labo, Tokyo, Japan
[2] Kyowa Hakko Kirin Co Ltd, Oncol Res Labo, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1101
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [21] Antitumor Activity of a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma
    Tu, Jianghua
    Toh, Yukimatsu
    Aldana, Adela M.
    Wen, Jake J.
    Wu, Ling
    Jacob, Joan
    Li, Li
    Pan, Sheng
    Carmon, Kendra S.
    Liu, Qingyun J.
    PHARMACEUTICS, 2024, 16 (07)
  • [22] In the spotlight: a novel CD37 antibody-drug conjugate
    Palomba, M. Lia
    Younes, Anas
    BLOOD, 2013, 122 (20) : 3397 - 3398
  • [23] Novel antibody-drug conjugate characterization by LC-MS
    不详
    BIOANALYSIS, 2011, 3 (15) : 1685 - 1685
  • [24] Development of a novel antibody-drug conjugate for refractory lymphoid malignancies
    Arita, Daigo
    Saijho, Sinji
    Matsumura, Yasuhiro
    Yasunaga, Masahiro
    CANCER SCIENCE, 2018, 109 : 389 - 389
  • [25] Novel targets and monoclonal antibodies for antibody-drug conjugate therapy
    Parri, Matteo
    Campagnoli, Susanna
    Grandi, Alberto
    De Camilli, Elisa
    Sarmientos, Paolo
    Jin, Boquan
    Grandi, Guido
    Viale, Giuseppe
    Terracciano, Luigi
    Pileri, Piero
    Grifantini, Renata Maria
    CANCER RESEARCH, 2015, 75
  • [26] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Wu, Szu-Yu
    Chen, Yu-Jung
    Lu, Chi-Huan
    Tu, Jyy-Shiuan
    Hsu, Ren-Yu
    Shia, Chi-Sheng
    Huang, Teng-Yi
    Lai, Ming-Tain
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175
  • [27] EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
    Capone, Emily
    Giansanti, Francesco
    Ponziani, Sara
    Lamolinara, Alessia
    Iezzi, Manuela
    Cimini, Annamaria
    Angelucci, Francesco
    La Sorda, Rossana
    De laurenzi, Vincenzo
    Natali, Pier Giorgio
    Ippoliti, Rodolfo
    Iacobelli, Stefano
    Sala, Gianluca
    ONCOTARGET, 2017, 8 (56) : 95412 - 95424
  • [28] Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
    Okajima, Daisuke
    Yasuda, Satoru
    Maejima, Takanori
    Karibe, Tsuyoshi
    Sakurai, Ken
    Aida, Tetsuo
    Toki, Tadashi
    Yamaguchi, Junko
    Kitamura, Michiko
    Kamei, Reiko
    Fujitani, Tomomichi
    Honda, Tomoyo
    Shibutani, Tomoko
    Muramatsu, Sumie
    Nakada, Takashi
    Goto, Riki
    Takahashi, Shu
    Yamaguchi, Miki
    Hamada, Hirofumi
    Noguchi, Yutaka
    Murakami, Masato
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2329 - 2340
  • [29] Effects of idiotypic human anti-mouse antibody against in vitro binding and antitumor activity of a monoclonal antibody-drug conjugate
    Otsuji, E
    Tsuruta, H
    Toma, A
    Kobayashi, S
    Okamoto, K
    Yata, Y
    Yamagishi, H
    HEPATO-GASTROENTEROLOGY, 2003, 50 (50) : 380 - 384
  • [30] IMMUNE SYSTEMS ENGAGEMENT RESULTS IN NON-CLASSICAL ANTIBODY-DRUG CONJUGATE ANTITUMOR ACTIVITY OF BRENTUXIMAB VEDOTIN
    Gardai, S. J.
    Heiser, R.
    Cao, A.
    Li, F.
    Leung-Law, C.
    HAEMATOLOGICA, 2016, 101 : 53 - 53
12345